Business Description
Starpharma Holdings Ltd
ISIN : US8555631022
Share Class Description:
SPHRY: ADRTotal Employee Number:
32Description
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 25.1 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.18 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 13.34 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 14.1 | |||||
3-Year EPS without NRI Growth Rate | 15.7 | |||||
3-Year FCF Growth Rate | 22.2 | |||||
3-Year Book Growth Rate | -27.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 91.86 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52 | |||||
9-Day RSI | 48.42 | |||||
14-Day RSI | 48.74 | |||||
3-1 Month Momentum % | 51.52 | |||||
6-1 Month Momentum % | 106.19 | |||||
12-1 Month Momentum % | 751.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.26 | |||||
Quick Ratio | 4.86 | |||||
Cash Ratio | 3.96 | |||||
Days Inventory | 570.6 | |||||
Days Sales Outstanding | 104.08 | |||||
Days Payable | 694.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | 0.49 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 90.67 | |||||
Operating Margin % | -35.08 | |||||
Net Margin % | -23.32 | |||||
EBITDA Margin % | -28.53 | |||||
FCF Margin % | -7.27 | |||||
OCF Margin % | -5.48 | |||||
ROE % | -15.23 | |||||
ROA % | -11.94 | |||||
ROIC % | -76.14 | |||||
3-Year ROIIC % | -437.18 | |||||
ROC (Joel Greenblatt) % | -95.16 | |||||
ROCE % | -21.92 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.24 | |||||
PS Ratio | 23.52 | |||||
PB Ratio | 14.39 | |||||
Price-to-Tangible-Book | 14.39 | |||||
EV-to-EBIT | -59.54 | |||||
EV-to-EBITDA | -73.41 | |||||
EV-to-Revenue | 20.5 | |||||
EV-to-Forward-Revenue | 9.92 | |||||
EV-to-FCF | -282.07 | |||||
Price-to-GF-Value | 1.49 | |||||
Price-to-Median-PS-Value | 0.57 | |||||
| Price-to-Net-Current-Asset-Value | 14.39 | |||||
| Price-to-Net-Cash | 23.75 | |||||
Earnings Yield (Greenblatt) % | -1.68 | |||||
FCF Yield % | -0.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SPHRY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Starpharma Holdings Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 9.166 | ||
| EPS (TTM) ($) | -0.051 | ||
| Beta | 1.6307 | ||
| 3-Year Sharpe Ratio | 0.56 | ||
| 3-Year Sortino Ratio | 1.21 | ||
| Volatility % | 101.69 | ||
| 14-Day RSI | 48.74 | ||
| 14-Day ATR ($) | 0.18862 | ||
| 20-Day SMA ($) | 4.84018 | ||
| 12-1 Month Momentum % | 751.79 | ||
| 52-Week Range ($) | 0.55 - 5.7 | ||
| Shares Outstanding (Mil) | 42.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Starpharma Holdings Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Starpharma Holdings Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Starpharma Holdings Ltd Frequently Asked Questions
What is Starpharma Holdings Ltd(SPHRY)'s stock price today?
The current price of SPHRY is $4.75. The 52 week high of SPHRY is $5.70 and 52 week low is $0.55.
When is next earnings date of Starpharma Holdings Ltd(SPHRY)?
The next earnings date of Starpharma Holdings Ltd(SPHRY) is .
Does Starpharma Holdings Ltd(SPHRY) pay dividends? If so, how much?
Starpharma Holdings Ltd(SPHRY) does not pay dividend.
Guru Commentaries on OTCPK:SPHRY
No articles.
Press Release
Articles on Starpharma Holdings Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers